Guiyang Xintian Pharmaceutical Co.,Ltd. - Laporan Laba Rugi (TTM)

Guiyang Xintian Pharmaceutical Co.,Ltd.
CN ˙ SZSE
CN¥ 11.69 ↑0.14 (1.21%)
2025-09-05
BAHAGING PRESYO
Laporan Laba Rugi (TTM)

Laporan Laba Rugi Guiyang Xintian Pharmaceutical Co.,Ltd. menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2022
01-01
2022
03-31
2022
06-30
2022
09-30
2023
01-01
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 726 751 865 902 954 970 1,004 1,040 1,094 1,088 1,047 1,089 994 954 923 870 839 858 873 774
Change (%) 3.44 15.22 4.26 5.79 1.62 3.56 3.58 5.14 -0.56 -3.72 3.99 -8.72 -4.04 -3.30 -5.72 -3.52 2.19 1.85 -11.36
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 157 166 187 191 202 201 209 221 241 248 242 255 231 219 213 210 214 231 247 222
Change (%) 5.70 12.83 2.09 5.67 -0.36 3.96 5.64 9.14 2.72 -2.12 5.26 -9.30 -5.20 -3.13 -1.00 1.94 7.56 6.86 -9.78
% of Revenue 21.62 22.09 21.63 21.18 21.15 20.74 20.82 21.23 22.04 22.77 23.15 23.43 23.28 23.00 23.04 24.19 25.56 26.90 28.23 28.73
Gross Operating Profit 569 585 678 711 752 769 795 819 853 840 805 834 763 735 710 659 625 627 627 552
Change (%) 2.82 15.89 4.86 5.82 2.16 3.46 3.04 4.06 -1.49 -4.19 3.61 -8.54 -3.68 -3.35 -7.13 -5.26 0.35 -0.00 -11.99
% of Revenue 78.38 77.91 78.37 78.82 78.85 79.26 79.18 78.77 77.96 77.23 76.85 76.57 76.72 77.00 76.96 75.81 74.44 73.10 71.77 71.27
SG&A 484 474 537 561 596 608 629 653 681 675 648 675 595 589 570 514 514 516 525 480
Change (%) -2.18 13.27 4.42 6.31 2.02 3.43 3.82 4.39 -1.02 -3.95 4.18 -11.90 -0.99 -3.13 -9.87 0.05 0.39 1.69 -8.51
% of Revenue 66.73 63.10 62.04 62.13 62.44 62.68 62.60 62.75 62.30 62.01 61.87 61.98 59.82 61.71 61.82 59.10 61.28 60.20 60.11 62.04
R&D 7 13 13 17 19 20 23 20 21 22 22 26 32 38 39 47 45 40 44 39
Change (%) 99.62 -4.93 35.53 13.67 4.63 11.30 -10.63 4.77 1.66 1.86 20.11 20.91 19.43 3.26 18.62 -3.38 -10.32 9.68 -11.72
% of Revenue 0.92 1.77 1.46 1.90 2.04 2.10 2.26 1.95 1.94 1.98 2.10 2.42 3.21 4.00 4.27 5.37 5.38 4.72 5.08 5.06
OpEx 656 665 750 783 831 843 874 907 959 957 925 968 870 857 833 785 785 799 828 754
Change (%) 1.28 12.81 4.44 6.19 1.42 3.68 3.74 5.69 -0.17 -3.36 4.69 -10.17 -1.48 -2.82 -5.76 0.02 1.86 3.58 -8.93
% of Revenue 90.38 88.50 86.64 86.79 87.12 86.95 87.04 87.18 87.63 87.98 88.31 88.90 87.49 89.81 90.26 90.22 93.52 93.22 94.81 97.42
Operating Income 70 86 116 119 123 127 130 133 135 131 122 121 124 97 90 85 54 58 45 20
Change (%) 23.75 33.77 3.11 3.15 2.99 2.80 2.51 1.40 -3.34 -6.39 -1.26 2.94 -21.89 -7.49 -5.34 -36.14 6.93 -22.03 -55.87
% of Revenue 9.62 11.50 13.36 13.21 12.88 13.05 12.96 12.82 12.37 12.02 11.69 11.10 12.51 10.19 9.74 9.78 6.48 6.78 5.19 2.58
Interest Expense -10 -5 -10 -13 -12 -17 -15 -10 -9 -11 -11 -16 -17 -12 -12 -17 -20 -18 -18 -13
Change (%) -42.62 79.40 30.65 -7.78 40.43 -7.28 -37.88 -3.78 16.00 5.43 40.98 7.20 -30.60 1.15 45.52 14.33 -11.54 4.00 -26.83
% of Revenue -1.31 -0.73 -1.13 -1.42 -1.24 -1.71 -1.53 -0.92 -0.84 -0.98 -1.07 -1.46 -1.71 -1.24 -1.29 -2.00 -2.37 -2.05 -2.09 -1.73
Net Income 63 74 96 96 102 101 106 111 117 112 106 100 94 81 71 65 54 52 41 28
Change (%) 17.83 30.03 -0.64 6.52 -1.35 5.48 4.80 4.80 -4.32 -5.19 -5.04 -6.03 -14.28 -11.77 -9.06 -16.53 -3.39 -21.76 -32.22
% of Revenue 8.66 9.87 11.14 10.61 10.69 10.37 10.57 10.69 10.66 10.25 10.10 9.22 9.49 8.48 7.73 7.46 6.45 6.10 4.69 3.58

Source: Capital IQ

Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista